Russian Pharmaceutical Industry Leader
18.10.2021
Pharmasyntez presented Saterex at the Rational Pharmacotherapy Congress
Pharmasyntez presented Saterex at the Rational Pharmacotherapy Congress

Vasily Afanasyev*, Doctor of Sciences (Medicine), clinical pharmacologist, presented a report entitled “DPP-4 inhibitors: a choice among equals”.

The report intended for medical practitioners presented a comparison of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. One of these drugs was Saterex (INN Gosogliptin), the first Russian original DPP-4 inhibitor manufactured by Pharmasyntez.

Saterex is recognized by the medical community. It is included in the list of vital and essential drugs (VED) and in the “Standards of specialized diabetes care”, 9th Edition (revised, 2019), the clinical practice guidelines of the Ministry of Health of the Russian Federation, the Russian Association of Endocrinologists, and the FGBI National Medical Research Centre of Endocrinology. 

The drug is convenient to use (once daily regimen) and affordable.

The qualitative characteristics of Saterex include:

  • activates the incretin response;
  • provides the glycemic control;
  • improves safety in terms of hypoglycemia;
  • effective as monotherapy and in combination with metformin;
  • has no effect on body weight.

* Vasily Vladimirovich Afanasyev - Professor of the Emergency Medical Care Department at the Surgery Faculty of I. I. Mechnikov North-Western State Medical University; leading research associate of the Research Department for Vascular and Interventional Surgery at Almazov National Medical Research Centre; chief toxicologist of the Leningrad Region.